AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06724744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Diaphragm Release
Description: The participant is asked assume a supine position with relaxed limbs. The therapist should position themselves at the head of the participant and make manual contact with the pisiform, hypothenar region, and the last three fingers on both sides, underneath the seventh to tenth rib costal cartilages. The therapist's forearms should be aligned towards the participant's shoulders. During the inspiratory phase, the therapist gently pulled the points of contact with both hands in the direction of the head and slightly laterally, accompanying the elevation of the ribs. Therapist progressively increases the depth of their contact within the costal margin.
Study NCT06722638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Virtual Reality Headset
Description: Virtual Reality Headsets will be used to augment pain and anxiety management during therapeutic LPs in children with acute lymphoblastic leukemia
Study NCT06722729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDT-3594
Description: Oral administration
Study NCT06722729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study NCT06722625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of a blood pressure monitoring system with an integrated algorithm that supports the doctor's decision-making process
Description: Receiving remote care facilitated by a specialized informatic system to support the physician
Study NCT06756282 — intervention group
Intervention type: PROCEDURE
Intervention: Pacemaker and defibrillator
Description: only patients with pacemaker implantation will be evaluated in the study
Study NCT06757270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Second arm: Using aleovera for Prevention and Treatment of Chemotherapy-Induced Oral Mucositis
Description: Second arm : aleovera 3 times daily after brushing teeth
Study NCT06757959 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Wet Needling
Description: This involve the use of needles to inject a local anesthetics into trigger points or areas of muscle tightness around the knee particularly in the quadriceps surrounding soft tissue implicated in patellofemoral pain syndrome .To reduce localized pain, release muscle tension and improve tissue function.
Study NCT06757959 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotaping
Description: Application of kinesiotape around knee joint or quadricep following a specific technique aimed at reducing pain and improving joint stability . The tape is typically applied to encourge proper movement patterns , reducing swelling and provide sensory feedback to brain. Strengthening exercises : To strenghthen the quadriceps , gluteal muscles and other key stabilizing muscles of lower limbs. This is aimed at reducing the mechanical stress on the joint and improve overall function.
Study NCT05680545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sevoflurane vaporized in ECMO machines
Description: Sevoflurane will be directly vaporized into the ECMO machine through the sweep gas.
Study NCT05993481 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure Measurement
Description: NIBP measurements will be recorded intraoperatively every 2.5 minutes for the group of 2.5 min. Blood pressure management or every 5 minutes for the other group of 5 min. Blood pressure management after providing randomization before the surgery. A calibrated and time-matched same type of standard anesthetic monitor will be used. The monitor will measure blood pressure and display the mean, systolic and diastolic values.~All blood pressure measurements will be discontinued before the PACU transfer. Data will be automatically downloaded from the monitor to a computer using a software interface program.
Study NCT04797572 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Free Margin Cusp Sizer
Description: The free margin cusp sizer will be used during aortic valve repair and sparing procedures as a caliper to measure the aortic valve free margin length.
Study NCT05792540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine 20 mg
Description: Fluoxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive-compulsive disorder and bulimia. It works by increasing the levels of serotonin in the brain
Study NCT05792540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin (DAPA), a sodium-glucose co-transporter 2 inhibitor (SGLT2-I), has proven to be an effective hyperglycemic suppressor due to its role in inhibiting the reabsorption of 30-50% of the glucose filtered by the kidney, besides its role in the improvement of insulin resistance
Study NCT05792540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg
Description: Atorvastatin is a synthetic and lipophilic statin, a class of drugs used in the treatment of hypercholesterolemia
Study NCT06304493 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Alarms
Description: The ON cohort patients will receive audible and visual signals from the InSee monitor attached to their incentive spirometer every 20 minutes and upon successfully reaching certain achievements.
Study NCT06304493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alarms
Description: The ON cohort patients will receive audible and visual signals from the InSee monitor attached to their incentive spirometer every 20 minutes and upon successfully reaching certain achievements.
Study NCT05628389 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational materials
Description: Patient educational materials to address insufficient knowledge about harms of tobacco use and cessation.
Study NCT05628389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational materials
Description: Patient educational materials to address insufficient knowledge about harms of tobacco use and cessation.
Study NCT05628389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone counseling
Description: Cessation counseling to address insufficient patient self-efficacy and motivation.
Study NCT05628389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Nicotine patches to address nicotine withdrawal symptoms in patients.
Study NCT05628389 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Provider training
Description: Provider training to address insufficient knowledge and self-efficacy to deliver AAA/AAC to patients.
Study NCT05628389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider training
Description: Provider training to address insufficient knowledge and self-efficacy to deliver AAA/AAC to patients.
Study NCT05628389 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Electronic reminders
Description: Electronic reminders to address the lack of integration of AAA/AAC into practice.
Study NCT05628389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic reminders
Description: Electronic reminders to address the lack of integration of AAA/AAC into practice.
Study NCT06019156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise video distribution of Metaverse
Description: Participants received a 10-minute exercise video each week with a load of about 4 to 8 metabolic equivalents of task (METs) in the metaverse space, for eight videos delivered to encourage exercise.
Study NCT06019156 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise video distribution of YouTube
Description: Participants view exercise videos with the same content as the metaverse group.
Study NCT05161338 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SERUM PROGESTERONE LEVELS
Description: Determination of serum P4 levels On the day of embryo transfer scheduling (prior to the onset of exogenous progesterone administration) and on the embryo transfer day-.
Study NCT05161338 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SERUM OESTRADIOL LEVELS
Description: Determination of serum E2 levels On the day of embryo transfer scheduling (prior to the onset of exogenous progesterone administration) and on the embryo transfer day.
Study NCT04862351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training for TechCR
Description: 3 times of supervised exercise training at the centre-based, outpatient cardiac rehabilitation clinic
Study NCT04862351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: audio/video conference
Description: weekly audio/video conference
Study NCT04862351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational video
Description: weekly for 6 weeks, duration of video about 10-15 minutes
Study NCT04862351 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Daily log
Description: daily dietary and exercise log
Study NCT04862351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily log
Description: daily dietary and exercise log
Study NCT04862351 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: exercise training for centre-based
Description: 6 times of supervised exercise training
Study NCT04272320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Ultrasound-guided Transversalis Fascia Plane Block with 0.5 ml/kg %0.25 bupivacaine
Study NCT04691570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX005
Description: ANX005 is provided as a solution for IV infusion
Study NCT04643158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1402
Description: Randomised participants will receive oral inhalation of AZD1402, via DPI.
Study NCT04643158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomised participants will receive oral inhalation of matching placebo via DPI.
Study NCT04643158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short acting beta agonist (SABA) (rescue medication)
Description: In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)
Study NCT04643158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Short acting beta agonist (SABA) (rescue medication)
Description: In addition to study intervention, all participants will be provided with a SABA as rescue medication (eg, salbutamol/albuterol), to be used throughout the Run-in and Treatment Periods. All participants should refrain from taking a SABA as rescue medication 6 hours prior to pulmonary function tests.~Dosage levels: 100 μg per nominal dose 90 μg per nominal dose pro re nata (as required) (PRN)
Study NCT04643158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Run-in medications (ICS-LABA combination)
Description: During the Run-in Period, the participants are required to maintain on their ICS-LABA dose. Controller medications (eg, ICS LABA) should remain at a stable dose and be taken after study intervention as applicable.~These drugs are used as standard of care.
Study NCT04643158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Run-in medications (ICS-LABA combination)
Description: During the Run-in Period, the participants are required to maintain on their ICS-LABA dose. Controller medications (eg, ICS LABA) should remain at a stable dose and be taken after study intervention as applicable.~These drugs are used as standard of care.
Study NCT04881149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TempSure treatment
Description: Self-controlled, single-arm study using the TempSure device.
Study NCT06436612 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy
Description: stereotactic body radiation therapy (SBRT) administered over 5 days x 5.0 - 6.0 Gy for patients with abdominopelvic sarcomas.
Study NCT06580756 — intervention group
Intervention type: OTHER
Intervention: Short training program
Description: Training in the early identification of addictive disorders in primary care
Study NCT06031558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-5007
Description: a RET selective Inhibitor
Study NCT06331169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.
Study NCT06331169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Trastuzumab deruxtecan is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor.
Study NCT05765500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Gonadotropin-releasing hormone (GnRH) antagonist, oral tablet taken 1x daily.
Study NCT05765500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: Gonadotropin-releasing hormone (GnRH) antagonist, intramuscular injection 1x every 3 months.
Study NCT05373108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan is a nonselective endothelin-receptor antagonist (ERA) that is approved for use in pulmonary arterial hypertension (PAH); the use of Macitentan in post-heart transplant patients is considered investigational.
Study NCT06534580 — intervention group
Intervention type: DEVICE
Intervention: Virtual Reality
Description: A range of virtual reality software, delivered through the DR.VR (TM) device.
Study NCT06308991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yakson touch
Description: Yakson touch method will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.The Yakson method continued for 15 minutes with steady touch (5 minutes), compassionate caressing (5 minutes), and repetition of steady touch (5 minutes).
Study NCT06308991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gentle Human Touch
Description: Gentle Human Touch (GHT) method will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.The GHT method continued for 15 minutes.
Study NCT06308991 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine care
Description: Infants in the Routine care will be applied swaddling. It will be started 5 minutes before the endotracheal aspiration procedure and continued until the completion of the procedure.
Study NCT05943912 — intervention group
Intervention type: OTHER
Intervention: Single Vision Spectacle Lens
Description: 36 months of therapy
Study NCT05943912 — intervention group
Intervention type: OTHER
Intervention: Defocus Incorporated Multiple Segments (DIMS) Spectacle Lens
Description: 36 months of therapy
Study NCT06276959 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: intraoral scanning
Description: The patients underwent intraoral scanning using an iTero Element 5D imaging system (Align Technology, San Jose, CA, USA). This imaging system uses near-infrared light with a wavelength of 850 nm and provides multiple layers of data in a single scan, including a three-dimensional (3D) model, two-dimensional (2D) color images, and NIRI mapped to the 3D model
Study NCT06276959 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: clinical oral examination
Description: Under illumination in the dental unit, a UVE of the proximal surfaces of the patient's entire dentition was conducted by clinicians using a mouth mirror, dental probe, and an air-water syringe. Visual and tactile methods were performed according to the guidelines of the American Dental Association. Clinicians assessed the soundness of the proximal surfaces based on the presence of discoloration, surface alterations, or cavitation.
Study NCT06276959 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cone-beam computed tomography
Description: All enrolled patients underwent CBCT scans because clear aligner treatment required real root/bone visualization features. We would like to clarify that due to the retrospective cross-sectional nature of this study, the patients involved were not subjected to radiation beyond what was initially necessary for their orthodontic treatment.
Study NCT05083988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality glasses
Description: a system composed of a head-mounted wide view display placed in front of the eyes and headphones placed in ears, it has the ability to block the real-world stimuli. This could distract the patient from the dental environment, which helps reduce anxiety
Study NCT05083988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: music
Description: Music can be used to distract patients from the anxiety provoking stimulus. It helps the patient to escape from the stressful reality as it activates imaginary. Psychosocially music can offer peace and comfort to patients during dental treatment as it helps in making the environment less threatening.
Study NCT05898971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic
Description: Patients receive robotic training (grasp and grip)
Study NCT05898971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror
Description: Patients receive mirror therapy
Study NCT05300256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Heating
Description: Peripheral heating of the feet
Study NCT05300256 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham
Study NCT06573034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daoist Zhanzhuang
Description: Each session of practice will last 30 minutes, and participants are expected to participate every day for 3 months. During the initial 3 weeks, participants will engage in in-person sessions 3 times a week. On non-session days, they can choose to either attend a Zoom practice session with the coach or submit a recording of their individual practice for fidelity check. In Week 4, participants will attend an in-person session for both practice and assessment. Over the subsequent 8 weeks, participants will either attend in-person or Zoom sessions, with a total of 3 check-in sessions.
Study NCT06573034 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham Wall Squat
Description: Same as the Zhanzhuang group.
Study NCT04120402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP-104IAR 25 mg
Description: Single 5 mL intra-articular injection
Study NCT04120402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Single 5 mL intra-articular injection
Study NCT05108818 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine
Description: The seasonal influenza vaccine is administered intramuscularly at a dose of 15 ug of HA per component, as approved by the FDA.
Study NCT04756986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: malic acid
Description: 1% malic acid spray
Study NCT06333613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS® 1-DAY with HydraLuxe™ TECHNOLOGY (AO1D)
Description: Test Lens
Study NCT05874921 — intervention group
Intervention type: DRUG
Intervention: Jelmyto (mitomycin) for pyelocalyceal solution
Description: The dose of Jelmyto to be instilled is 4 mg per mL via ureteral catheter or a nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin).~Instill Jelmyto once weekly for six weeks. For patients with a complete response 3 months after Jelmyto initiation, Jelmyto instillations may be administered once a month for a maximum of 11 additional instillations.
Study NCT05898971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: Traditional exercise and Neurophysiological approaches
Study NCT05305066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNFi
Description: TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein) 50 mg sc per week, adalimumab (monoclonal antibody) 40 mg sc every 2 weeks, golimumab (monoclonal antibody) 50 mg sc every month, or certolizumab (pegylated fragment of a monoclonal antibody) 400 mg sc at week 0, 2 and 4, and then 200 mg sc every 2 weeks or 400 mg sc every 4 weeks.
Study NCT04726319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FHAMe Intervention
Description: Patients will receive an invitation email prior to their scheduled clinical visit which includes information about the study, a link to the YouTube patient presentation, and a link to the consent form and questionnaire. Patients will be invited to fill out the questionnaire prior to their appointment. After patients complete the initial questionnaire, physicians will receive an EMR message on the day of patient's clinic visit alerting them that patient family history information is available and to complete the Family History Action Form. They will be prompted to respond to the message which will open the action form and ask what action the provider intends to take with this family history information. The form will then link to management support tools for use during the patient visit. All participants will attend their clinical visit after which they will receive a post-visit electronic survey regarding their clinical visit and whether family history was reviewed with their provider.